John L. Haslam

1.1k total citations
34 papers, 777 citations indexed

About

John L. Haslam is a scholar working on Pharmaceutical Science, Molecular Biology and Organic Chemistry. According to data from OpenAlex, John L. Haslam has authored 34 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmaceutical Science, 8 papers in Molecular Biology and 6 papers in Organic Chemistry. Recurrent topics in John L. Haslam's work include Drug Solubulity and Delivery Systems (6 papers), Analytical Chemistry and Chromatography (3 papers) and Pharmacological Effects of Natural Compounds (3 papers). John L. Haslam is often cited by papers focused on Drug Solubulity and Delivery Systems (6 papers), Analytical Chemistry and Chromatography (3 papers) and Pharmacological Effects of Natural Compounds (3 papers). John L. Haslam collaborates with scholars based in United States, Canada and Belgium. John L. Haslam's co-authors include Siegfried Lindenbaum, Gordon L. Amidon, M. Vadnere, Gordon G. Hammes, Venkatramana M. Rao, Valentino J. Stella, Valentino J. Stella, Edward M. Eyring, Tsunehiko Higuchi and Noboru Yata and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Journal of Molecular Biology.

In The Last Decade

John L. Haslam

34 papers receiving 693 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John L. Haslam United States 15 297 175 143 114 100 34 777
Naoki Nambu Japan 21 1.0k 3.4× 272 1.6× 144 1.0× 216 1.9× 247 2.5× 60 1.5k
Anna Kogan Israel 11 415 1.4× 178 1.0× 302 2.1× 45 0.4× 121 1.2× 19 845
Gábor Vasvári Hungary 17 262 0.9× 216 1.2× 107 0.7× 216 1.9× 115 1.1× 49 929
Dane O. Kildsig United States 20 493 1.7× 188 1.1× 160 1.1× 213 1.9× 241 2.4× 64 1.2k
Tamaki Miyazaki Japan 16 390 1.3× 151 0.9× 88 0.6× 162 1.4× 286 2.9× 42 793
Jingling Tang China 17 299 1.0× 274 1.6× 69 0.5× 39 0.3× 126 1.3× 42 1.1k
Reinhard Neubert Germany 10 122 0.4× 241 1.4× 178 1.2× 100 0.9× 40 0.4× 11 580
Jim H. Kou United States 12 229 0.8× 93 0.5× 67 0.5× 50 0.4× 28 0.3× 14 583
E. Berlin United States 17 52 0.2× 158 0.9× 63 0.4× 74 0.6× 103 1.0× 39 1.1k
Fuzheng Ren China 15 283 1.0× 181 1.0× 55 0.4× 78 0.7× 156 1.6× 40 764

Countries citing papers authored by John L. Haslam

Since Specialization
Citations

This map shows the geographic impact of John L. Haslam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Haslam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Haslam more than expected).

Fields of papers citing papers by John L. Haslam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Haslam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Haslam. The network helps show where John L. Haslam may publish in the future.

Co-authorship network of co-authors of John L. Haslam

This figure shows the co-authorship network connecting the top 25 collaborators of John L. Haslam. A scholar is included among the top collaborators of John L. Haslam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Haslam. John L. Haslam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vieito, María, Anna Spreafico, Víctor Moreno, et al.. (2020). 537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers. Annals of Oncology. 31. S470–S470. 19 indexed citations
2.
Weir, Scott J., Prabhu Ramamoorthy, John L. Haslam, et al.. (2018). Preclinical development of ciclopirox prodrug for the treatment of non-muscle invasive and muscle invasive bladder cancer.. Journal of Clinical Oncology. 36(15_suppl). e14576–e14576. 4 indexed citations
3.
Reid, Joel M., Chad A. Walden, Rui Qin, et al.. (2011). Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668. Cancer Prevention Research. 4(3). 347–353. 16 indexed citations
4.
Kapetanović, Izet M., Miguel Muzzio, James A. Crowell, et al.. (2009). Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys. Cancer Chemotherapy and Pharmacology. 65(6). 1109–1116. 14 indexed citations
5.
6.
7.
Lubach, Joseph W., et al.. (2007). Characterization of Prednisolone in Controlled Porosity Osmotic Pump Pellets using Solid-State NMR Spectroscopy. Journal of Pharmaceutical Sciences. 96(5). 1008–1017. 9 indexed citations
8.
Haslam, John L., et al.. (2006). Evaluation of various properties of alternative salt forms of sulfobutylether-β-cyclodextrin, (SBE)7M-β-CD. International Journal of Pharmaceutics. 330(1-2). 73–81. 19 indexed citations
9.
Yasuji, Takehiko, et al.. (2006). Preliminary Evaluation of Polymer-Based Drug Composite Microparticle Production by Coacervate Desolvation with Supercritical Carbon Dioxide. Journal of Pharmaceutical Sciences. 95(3). 581–588. 5 indexed citations
10.
Rao, Venkatramana M., John L. Haslam, & Valentino J. Stella. (2001). Controlled and complete release of a model poorly water‐soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE)7m‐β‐cyclodextrin as a solubilizing agent. Journal of Pharmaceutical Sciences. 90(7). 807–816. 61 indexed citations
11.
Haslam, John L., et al.. (1998). Tableting of controlled release multiparticulates, the effect of millisphere size and protective overcoating. International Journal of Pharmaceutics. 173(1-2). 233–242. 21 indexed citations
12.
Vadnere, M., Gordon L. Amidon, Siegfried Lindenbaum, & John L. Haslam. (1984). Thermodynamic studies on the gel-sol transition of some pluronic polyols. International Journal of Pharmaceutics. 22(2-3). 207–218. 273 indexed citations
13.
Sloan, Kenneth B., et al.. (1984). Acyloxyamines as Prodrugs of Anti-inflammatory Carboxylic Acids for Improved Delivery Through Skin. Journal of Pharmaceutical Sciences. 73(12). 1734–1737. 16 indexed citations
14.
Haslam, John L., et al.. (1974). Kinetic investigation of the interaction of serine transhydroxymethylase with glycine and serine. Biochemistry. 13(15). 3079–3085. 7 indexed citations
15.
Haslam, John L., et al.. (1974). Immobilized enzyme electrode for the determination of arginase. Analytical Chemistry. 46(8). 1054–1060. 22 indexed citations
16.
Haslam, John L.. (1972). Calculation of rate constants from relaxation spectra of enzyme reactions. The Journal of Physical Chemistry. 76(3). 366–369. 6 indexed citations
17.
Hammes, Gordon G. & John L. Haslam. (1969). Kinetic investigation of the interaction of erythro-β-hydroxyaspartic acid with aspartate aminotransferase. Biochemistry. 8(4). 1591–1598. 44 indexed citations
18.
Eyring, Edward M. & John L. Haslam. (1966). Solvent Deuterium Isotope Effects on Intramolecularly Hydrogen-Bonded Dicarboxylic Acid Monoanions1. The Journal of Physical Chemistry. 70(1). 293–296. 3 indexed citations
19.
Haslam, John L., et al.. (1952). The determination of nickel and manganese in uranium. The Analyst. 77(918). 464–464. 2 indexed citations
20.
Haslam, John L., et al.. (1952). The determination of fluorine in polytetrafluoroethylene. Journal of Applied Chemistry. 2(6). 339–344. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoki Nambu Breakdown of academic impact, for papers by Anna Kogan Breakdown of academic impact, for papers by Gábor Vasvári Breakdown of academic impact, for papers by Dane O. Kildsig Breakdown of academic impact, for papers by Tamaki Miyazaki Breakdown of academic impact, for papers by Jingling Tang Breakdown of academic impact, for papers by Reinhard Neubert Breakdown of academic impact, for papers by Jim H. Kou Breakdown of academic impact, for papers by E. Berlin Breakdown of academic impact, for papers by Fuzheng Ren
Rankless by CCL
2026